Top Featured

Take a peek at who will be joining us 14-16 May, 2024 in Brussels, Belgium for the highly anticipated Clinical Trial Supply Forum...

Alexandra Tsioni, Associate Director, Clinical Supply Chain Global Lead, Israel, brilliantly presented a 'Direct-to-Patient Case Study' at the Clinical Trial Supply Forum 2022. 

Download your copy to learn more about: 

• The impact of COVID-19 on clinical trials 
• Direct-to-patient vs traditional approaches 
• The impact on clinical supplies 
• Direct-to-patient case study considerations, challenges and mitigations

Building reverse logistics and product reconciliations into your supply strategy to optimise end to end distribution management was delivered at the Clinical Trial Supply Forum 2022 by Kamal Amin, Head of Supply Management, Galderma.

Download your copy to discover:

• The role of clinical supplies teams within the reverse logistics and reconciliations management strategy 
• Where your returns and reconciliations fit into your end-to-end clinical supply lifecycle
• Ways to reduce unforeseen costs through flexible product return and destruction strategies 
• End-to-end alignment in supply management by effectively engaging your clinical teams across the process implementation lifecycle 

In the realm of clinical trials, patient recruitment poses a significant challenge, with merely 2%-5% of U.S. patients currently engaged in these crucial research endeavors. Patients represent the cornerstone of any clinical trial, without whom progress in developing novel therapies and advancing care innovation would stall. Consequently, ensuring patient participation and completion stands as a primary focus for clinical trial sponsors. While extensive research has been dedicated to understanding barriers to participation, such as access and indirect expenses like travel and lodging, another critical factor hindering participation and exacerbating patient drop-out emerges: the coverage of care for baseline or comparator drugs in the U.S., which contrasts with other countries like the U.K. where sponsors typically bear such costs. This disparity in coverage may disproportionately impact socio-economically vulnerable and diverse patient populations, potentially impeding their access to and engagement in vital clinical trials.

Dive into the whitepaper today to explore:

• The current state of care coverage in cancer trials
• Developing a framework to understand sponsor coverage impact
• Cost of noncoverage versus cost of coverage
• A case for coverage